hMSC exosomes as a novel treatment for female sensitive skin: An in vivo study

Abstract

Background: Recent studies have reported that the incidence of sensitive skin is increasing. Skin sensitivity and skin barrier functions were related to many skin diseases including atopic dermatitis, psoriasis, rosacea, and so on. Mesenchymal stem cell (MSC)-derived exosomes (hMSC) might be considered as a new effective therapeutic scheme.Aims: This study aims to investigate the safety and efficacy of hMSC exosomes as a novel topical treatment for sensitive skin.Patients/Methods: Exosomes were extracted from primary hMSC via ultracentrifugation method. The morphology of hMSC exosomes was studied via transmission electron microscope. Expression of exosome specific surface marker was detected via Western blot. 22 subjects (female, aged 18–55) diagnosed with sensitive skin were enrolled. Follow-up was conducted before, 7-day, 14-day, and 28-day after hMSC exosomes use. Transepidermal water loss (TEWL), surface hydration, sebum secretion, and L*a*b* value were simultaneously tested at the same time point in an environment-controlled room.Results: Under transmission electron microscopy, the extracted hMSC exosomes were circular or elliptical with intact membrane structure, and their diameters ranged mainly from 40 to 80 nm. Western blot showed that the expression of markers CD63, CD9, and Tsg101 was positive. Brownian motion based nanoparticle trajectory analysis (NTA) showed that the main peak of particle size distribution occurred around 96 nm, the average particle size was 122 nm, and the main peak accounted for 96.7%. All this conformed to the biological characteristics of exosomes standardized by the International Society for Extracellular Vesicles. In the clinical trial, scores of objective symptoms including roughness, scales, erythema, and subjective symptoms including tension, burning, or itching, were improved after 7-, 14-, and 28- day using hMSC-exosomes. TEWL, hydration, sebum, pH, and a* values were tended to return to the level of healthy skin.Conclusion: The hMSC-exosomes, with the advantages of biocompatibility and biodegradability, could improve clinical symptoms and eruptions in sensitive skin patients, and might be as an MSC cell-free novel therapy in sensitive skin-related disease treatment.

The Innovative and Evolving Landscape of Topical Exosome and Peptide Therapies: A Systematic Review of the Available Literature

“…In the discussion of cosmesis improvement, Ye et al found that exosome treatment improved sensitive skin scoring of roughness, scaling, erythema, as well as burning, tension, itching, and dryness, as assessed by 1 professional dermatologist on an objective and subjective sensitive skin index. 16 Proffer et al found that exosome treatment produced improvements in facial aging, such as erythema, color evenness, luminosity, wrinkling, and firmness, as measured by computer analysis of photo documentation. 15 Both of these studies excluded anyone who had prior dermatologic or cosmetic procedures, excluding a large population that would potentially be interested in this type of product.…”

“…Current studies, such as those included in this systematic literature review, focused on skin outcomes over a period of weeks. 16-25 There are currently no studies assessing the long-term implications of topical exosome products.…”

Extracellular vesicles as human therapeutics: A scoping review of the literature

“…Four of the evaluated publications describe the topical application of EVs for the treatment of dermatologic conditions. The first study, conducted in China, enrolled 22 female subjects with sensitive skin to be treated with EVs released by primary human MSCs (study n.31, Table 1 ) (Ye et al., 2022 ). Skin sensitivity, including atopic dermatitis and rosacea, is a condition of subjective cutaneous hyper‐reactivity to environmental factors such as cold, heat, and wind (Berardesca et al., 2013 ); its mean prevalence among Chinese women reaches 15%, detrimentally influencing life quality of millions of individuals (Xu et al., 2013 ).…”

“…Skin sensitivity, including atopic dermatitis and rosacea, is a condition of subjective cutaneous hyper‐reactivity to environmental factors such as cold, heat, and wind (Berardesca et al., 2013 ); its mean prevalence among Chinese women reaches 15%, detrimentally influencing life quality of millions of individuals (Xu et al., 2013 ). MSC‐EVs were reported to improve scores of objective symptoms (e.g., roughness and erythema), and subjective symptoms, such as tension, burning, or itching, upon treatment (Ye et al., 2022 ). Other two of those studies were performed in Korea and aimed at treating individuals with facial redness subsequent to a specific biological treatment for atopic dermatitis (Dupilumab).…”

Umbilical cord‐derived mesenchymal stem cell secretome promotes skin regeneration and rejuvenation: From mechanism to therapeutics

“…Finally, UCMSC‐exo can reduce skin sensitivity and restore skin barrier function. In clinical use, it ameliorates roughness, erythema, tension, burning, and itching in patients with skin sensitivity, and treats melasma 104,105 …”